Holzer begins infusion therapy for COVID-19 patients
Staff Report
GALLIPOLIS Holzer Health System is now offering specialty infusions for COVID-19 patients meeting specified criteria. These infusions are taking place in a dedicated treatment area at the Gallipolis campus.
According to a news release from Holzer, the newly assigned treatment area allows Holzer to provide infusion therapy to recently diagnosed COVID-19 patients that are at high risk for hospitalization. Patients will receive an infused therapy of a new monoclonal antibody, Bamlanivimab (BAM), that has received emergency use authorization through the US Food and Drug Administration.
“Providing newly approved infusion therapies allows Holzer to be proactive with COVID-19 treatment and potentially reduce hospitalizations in our community,” stated Lisa Detty, MSN, RN, executive vice president of nursing and chief nursing officer, Holzer Health System.